IHC - Leu 1 - CD15

The IHC – Leu 1 (CD15) test is a specialized immunohistochemistry (IHC) diagnostic test used to detect CD15 antigen expression in tissue samples. CD15 is a cell surface marker commonly found on certain white blood cells and is an important diagnostic marker in hematopathology, especially for identifying classical Hodgkin lymphoma.

CD15 is frequently expressed on Reed-Sternberg cells, which are characteristic abnormal cells seen in classical Hodgkin lymphoma. Detecting CD15 helps pathologists distinguish Hodgkin lymphoma from other lymphoid cancers and reactive conditions. It is also used in combination with other markers such as CD30, CD20, CD45, and PAX5 for accurate diagnosis and classification.

The Leu 1 (CD15) test is an essential part of lymphoma evaluation and provides valuable information for treatment planning and prognosis assessment.

Benefits of the Test

The IHC CD15 test offers several important benefits:

• Detects CD15 antigen in tissue samples
• Supports diagnosis of classical Hodgkin lymphoma
• Helps identify Reed-Sternberg cells
• Differentiates Hodgkin lymphoma from non-Hodgkin lymphoma
• Improves accuracy in hematopathology diagnosis
• Supports personalized treatment planning

This test helps ensure precise classification of lymphoid malignancies.

Why Doctors Recommend This Test

Doctors recommend the CD15 IHC test when lymphoma is suspected or when biopsy findings need further confirmation.

It is commonly advised for:

• Enlarged lymph node evaluation
• Suspected Hodgkin lymphoma
• Lymphoid tissue biopsy analysis
• Differentiation of lymphoma subtypes
• Advanced hematopathology workup

The results help hematologists and oncologists confirm diagnosis and choose the most appropriate therapy.

Preparation Before Test

No special preparation is required from the patient. The test is performed on tissue biopsy samples already collected during routine diagnostic procedures such as lymph node biopsy.

Normal Reporting Time

The usual reporting time for the Leu 1 (CD15) IHC test is 2 to 4 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with suspected Hodgkin lymphoma
• Individuals with enlarged lymph nodes
• Patients requiring lymphoma subtype confirmation
• Cases needing Reed-Sternberg cell identification
• Oncology patients undergoing lymphoid tissue analysis

The IHC Leu 1 (CD15) test is an important diagnostic tool in hematopathology. It provides accurate identification of CD15-positive cells and supports early diagnosis of Hodgkin lymphoma. Timely diagnosis enables effective treatment planning and improves patient outcomes.